Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer (Q24647897)

0 references

G Ahlgren

0 references

O Nordle

0 references

A Björk

0 references

J-E Damber

British Journal of Cancer

0 references

language of work or name

English

0 references

publication date

20 October 2009

0 references

published in

0 references

volume

101

0 references

issue

0 references

page(s)

1233-40

0 references

cites work

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

The role of angiogenesis inhibitors in prostate cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

Sorafenib for the treatment of advanced renal cell carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

A history of prostate cancer treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

30 May 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605322

Cancer incidence and mortality in Europe, 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605322

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605322

EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605322

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605322

Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605322

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605322

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605322

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768463

28 November 2018

1 reference

12 December 2020

Anti-angiogenesis: new concept for therapy of solid tumors

1 reference

PubMed

12 December 2020

An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma

1 reference

PubMed

12 December 2020

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6605322

1 reference

Dimensions Publication ID

1006235447

0 references

1 reference

1 reference

PubMed publication ID

19755981

1 reference